Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?
Rheumatol Int
; 36(11): 1601-1607, 2016 Nov.
Article
em En
| MEDLINE
| ID: mdl-27638722
ABSTRACT
Rheumatoid arthritis (RA) is a chronic, inflammatory, multi-systemic autoimmune disease unremitted by genetic and environmental factors. The factors are crucial but inadequate in the development of disease; however, these factors can be representative of potential therapeutic targets and response to clinical therapy. Insights into the contribution of genetic risk factors are currently in progress with studies querying the genetic variation, their role in gene expression of coding and non-coding genes and other mechanisms of disease. In this review, we describe the significance of genetic markers architecture of RA through genome-wide association studies and meta-analysis studies. Further, it also reveals the mechanism of disease pathogenesis investigated through the mutual findings of functional and genetic studies of individual RA-associated genes, which includes HLA-DRB1, HLA-DQB1, HLA-DPB1, PADI4, PTPN22, TRAF1-C5, STAT4 and C5orf30. However, the genetic background of RA remains to be clearly depicted. Prospective efforts of the post-genomic and functional genomic period can travel toward real possible assessment of the genetic effect on RA. The discovery of novel genes associated with the disease can be appropriate in identifying potential biomarkers, which could assist in early diagnosis and aggressive treatment.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Marcadores Genéticos
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article